Atara Biotherapeutics, Inc. (LON: 0HIY)
London
· Delayed Price · Currency is GBP · Price in USD
6.49
+0.36 (5.93%)
Jan 22, 2025, 7:14 PM BST
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $40.19M USD in the quarter ending September 30, 2024, with 1,779.79% growth. This brings the company's revenue in the last twelve months to $100.44M, up 2,111.34% year-over-year. In the year 2023, Atara Biotherapeutics had annual revenue of $8.57M, down -86.51%.
Revenue (ttm)
$100.44M
Revenue Growth
+2,111.34%
P/S Ratio
n/a
Revenue / Employee
$446.40K
Employees
225
Market Cap
32.22M GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Atara Biotherapeutics News
- 4 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - Accesswire
- 6 days ago - Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application - GuruFocus
- 6 days ago - Atara down 46% as FDA declines to approve organ, bone marrow transplant therapy - Seeking Alpha
- 7 days ago - US FDA declines to approve Atara Biotherapeutics' cancer therapy - Reuters
- 7 days ago - Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) - Business Wire
- 2 months ago - Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 2 months ago - Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference - Business Wire
- 2 months ago - Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress - Business Wire